These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 17217865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP.
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. RNA interference--significance and applications.
    Stanisławska J, Olszewski WL.
    Arch Immunol Ther Exp (Warsz); 2005 Oct; 53(1):39-46. PubMed ID: 15761375
    [Abstract] [Full Text] [Related]

  • 6. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y, Nishikawa M, Takakura Y.
    Adv Drug Deliv Rev; 2009 Jul 25; 61(9):760-6. PubMed ID: 19386274
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. RNA-mediated gene silencing: mechanisms and its therapeutic applications.
    Verma NK, Dey CS.
    J Clin Pharm Ther; 2004 Oct 25; 29(5):395-404. PubMed ID: 15482382
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA.
    Aigner A.
    Expert Opin Biol Ther; 2009 Dec 25; 9(12):1533-42. PubMed ID: 19769540
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A.
    Curr Opin Mol Ther; 2007 Aug 25; 9(4):345-52. PubMed ID: 17694447
    [Abstract] [Full Text] [Related]

  • 14. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y, Li Z, Li L, Li J, Liu X, Li W.
    Int J Mol Med; 2007 Apr 25; 19(4):705-11. PubMed ID: 17334648
    [Abstract] [Full Text] [Related]

  • 15. The silent treatment: siRNAs as small molecule drugs.
    Dykxhoorn DM, Palliser D, Lieberman J.
    Gene Ther; 2006 Mar 25; 13(6):541-52. PubMed ID: 16397510
    [Abstract] [Full Text] [Related]

  • 16. [Application of RNAi in gene-deficient models].
    Tan YL, Yin QW.
    Yi Chuan Xue Bao; 2005 Apr 25; 32(4):434-41. PubMed ID: 16011036
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic application of RNA interference for hepatitis C virus.
    Watanabe T, Umehara T, Kohara M.
    Adv Drug Deliv Rev; 2007 Oct 10; 59(12):1263-76. PubMed ID: 17822803
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Application of RNAi technology to knockdown gene expression in vivo in mammalians].
    Zhang AH, Liu GQ.
    Sheng Li Ke Xue Jin Zhan; 2004 Apr 10; 35(2):125-9. PubMed ID: 15285417
    [Abstract] [Full Text] [Related]

  • 20. siRNA-based approaches in cancer therapy.
    Devi GR.
    Cancer Gene Ther; 2006 Sep 10; 13(9):819-29. PubMed ID: 16424918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.